Literature DB >> 959568

Prostaglandin removal and metabolism by isolated perfused rat lung.

M W Anderson, T E Eling.   

Abstract

We have investigated the mechanism(s) involved in the removal of prostaglandins (PG) from the pulmonary circulation by the lung. Unidirectional fluxes of PG from the circulation into the lung are measured in an isolated perfused rat lung preparation. Evidence is presented which suggests that a transport system for PG exists in lung tissue. This transport system is responsible for the removal of some PG from the circulation by the lung. PGE1 and PGF2alpha are substrates for this system, whereas PGB1, PGA1, and 15-keto-PGF2alpha are not. Since PGA1 is a substrate for the intracellular PG dehydrogenase, the selectivity of the lung's metabolism system for circulating PG is probably due to the selectivity of the transport system for PG. It is shown that the percentage of the pulmonary arterial concentration (CA) of PGE1 or PGF2alpha that is metabolized on passage through the pulmonary circulation decreases rapidly as CA increases. When the lungs were perfused with PGE1(PGF2alpha), the metabolites detected in the venous effluent were 15-keto-PGE1 (PGF2alpha) and 15-keto-13, 14-dihydro-PGE1 (PGF2alpha). The time course pattern of the appearance of metabolites in the venous effluent after the initiation of a constant CA, and the relative concentrations of the metabolites in the venous effluent, were examined as a function of CA.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 959568     DOI: 10.1016/0090-6980(76)90067-8

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  15 in total

Review 1.  Roles of Organic Anion Transporting Polypeptide 2A1 (OATP2A1/SLCO2A1) in Regulating the Pathophysiological Actions of Prostaglandins.

Authors:  Takeo Nakanishi; Ikumi Tamai
Journal:  AAPS J       Date:  2017-12-04       Impact factor: 4.009

2.  Alteration of fate of vasoactive autacoids in pulmonary circulation following monocrotaline-induced lung vascular injury in rats.

Authors:  K Ito; K Hayashi; T Nakashima; T Murakami
Journal:  Br J Pharmacol       Date:  1988-08       Impact factor: 8.739

3.  Inhibition of pulmonary prostaglandin metabolism by exposure of animals to oxygen or nitrogen dioxide.

Authors:  A Chaudhari; K Sivarajah; R Warnock; T E Eling; M W Anderson
Journal:  Biochem J       Date:  1979-10-15       Impact factor: 3.857

4.  Effect of nafazatrom and indomethacin on pulmonary removal of prostaglandin E1 after endotoxin in rabbits.

Authors:  C N Gillis; A M Havill; R Moalli
Journal:  Br J Pharmacol       Date:  1987-08       Impact factor: 8.739

5.  Uptake and inactivation of prostaglandin E2 methyl analogues in the rat pulmonary circulation.

Authors:  Y S Bakhle; S Jancar; B J Whittle
Journal:  Br J Pharmacol       Date:  1978-02       Impact factor: 8.739

6.  Selective inhibition of thromboxane B2 accumulation and metabolism in perfused guinea-pig lung.

Authors:  J R Hoult; C Robinson
Journal:  Br J Pharmacol       Date:  1983-01       Impact factor: 8.739

7.  Urinary oxidative stress biomarkers and accelerated time to spontaneous delivery.

Authors:  Emma M Rosen; Thomas J van 't Erve; Jonathan Boss; Sheela Sathyanarayana; Emily S Barrett; Ruby H N Nguyen; Nicole R Bush; Ginger L Milne; Thomas F McElrath; Shanna H Swan; Kelly K Ferguson
Journal:  Free Radic Biol Med       Date:  2018-11-14       Impact factor: 7.376

8.  Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT).

Authors:  R Lu; N Kanai; Y Bao; V L Schuster
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

9.  Effect of sulphasalazine on pulmonary inactivation of prostaglandin F2 alpha in the pig.

Authors:  P G Hellewell; J D Pearson
Journal:  Br J Pharmacol       Date:  1982-06       Impact factor: 8.739

10.  Effects of cigarette smoke on the metabolism of vasoactive hormones in rat isolated lungs.

Authors:  Y S Bakhle; J Hartiala; H Toivonen; P Uotila
Journal:  Br J Pharmacol       Date:  1979-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.